# Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Study · id `cardio:ct-nct02406677` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02406677](<https://clinicaltrials.gov/study/NCT02406677>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02406677

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11001 participants.

## Technical summary

Registry record NCT02406677. Randomized; no masking; primary purpose health services research. Start 2015-06-05 (actual); primary completion 2017-10-23 (actual). Results posted on 2019-10-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose health services research
- Phase: Phase 4
- Enrolled: 11001 participants (enrolled count; ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Started: 2015-06-05 (actual) (ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Primary completion: 2017-10-23 (actual) (ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Completion: 2017-10-23 (actual) (ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Results first posted: 2019-10-01 (ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT02406677, source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02406677-2019-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
- Acronym: ARTEMIS
- Condition: Cost Sharing, Acute Coronary Syndrome
- Intervention (Other): Study voucher card
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial (`cardio:pubmed-30620370`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial (`cardio:pubmed-31721978`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs (`cardio:pubmed-32299284`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial (`cardio:pubmed-32129795`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial (`cardio:pubmed-32393129`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS (`cardio:pubmed-36250667`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial (`cardio:pubmed-37301758`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a13c94116c95add4bab2d9fc9ed6aae0a9ecfcfc85e2e7cb9765aca201a0a493
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
